Cover Image
市場調查報告書

非酒精性脂肪性肝炎(NASH)(開發平台分析,藥物級,臨床試驗,地區)的全球市場

Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) 2013 - 2020

出版商 Allied Market Research 商品編碼 310284
出版日期 內容資訊 英文 75 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非酒精性脂肪性肝炎(NASH)(開發平台分析,藥物級,臨床試驗,地區)的全球市場 Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) 2013 - 2020
出版日期: 2014年08月01日 內容資訊: 英文 75 Pages
簡介

非酒精性脂肪性肝炎(NASH)可說是無症狀的肝臟疾病之一,會影響糖尿病及肥胖患者。NASH的症狀雖然所有年齡層都會出現,但好發於年輕人身上。非酒精性脂肪性肝炎市場預測在2014∼2020年間將以CAGR25.6%的速度成長,最後達到16億9,320萬美元的規模。

本報告提供全球非酒精性脂肪性肝炎市場相關調查分析,為您彙整市場概要,開發平台分析,藥物級,臨床試驗,各地區的考察,主要企業簡介等相關資訊。

第1章 簡介

第2章 摘要整理

第3章 市場預測

  • 中度成長方案
  • 急速成長方案
  • 低成長方案

第4章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • NASH的預防機會
  • 果糖的預防效果相關的爭議
  • 非酒精性脂肪肝病患者的許可事項,禁止事項
  • 亞太地區非酒精性脂肪肝病蔓延
  • 開發平台治療
  • 診斷技術
  • 治療方法
  • 臨床試驗
  • 市場動態

第5章 全球非酒精性脂肪性肝炎市場:各藥物類型

  • GFT505
  • Obeticholic Acid (INT-747)
  • Simtuzumab/Liraglutide (Victoza)
  • 維他命E
  • Poglitazone
  • Placebo

第6章 全球非酒精性脂肪性肝炎市場(開發平台藥物分析):各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美/中東/非洲

第7章 企業簡介

  • Genfit
  • Gilead Science
  • Novo Nordisk
  • Intercepts Pharmaceuticals
  • Enzo Biochem, Inc.
  • Raptor Pharmaceutical Corp.

圖表

目錄
Product Code: PH 14224

Title: Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020.

Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase . Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Global non-alcoholic Steatohepatitis market is expected to garner $1693.2 million by 2020 growing at a CAGR of 25.6% during 2014-2020.

Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017. The market growth is restricted by factors such as NASH's complex and enigmatic physiological structure and inefficient diagnostics technology; these factors could also prolong the commercialization process for NASH therapeutics. Nevertheless, certain key players competing in the market are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. The results of a recent clinical trial conducted by Genfit satisfied concerns of the EMA (European Medicines Agency), regarding the efficacy and safety of GFT5o5 as therapeutics for NASH. The EMA finally recommended that the development of GFT5o5 as a therapeutic drug progress to Phase III of the clinical trial. Additionally, Dainippon Sumitomo Pharma (DSP), a partner of Intercept Pharmaceuticals, initiated a phase 2 clinical trial to test the safety and efficacy of one daily dose of OCA in 200 adult NASH patients. The trial is expected to be completed in the first half of 2016.

Geographically, the NASH therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Geographical analysis of NASH therapeutics is conducted with reference to research and commercialization. North America, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. It is also one of the regions with the most cases of NASH and other non-alcoholic fatty liver diseases. European countries are equally contributing to the growth of the NASH therapeutics market in terms of research and commercialization; however, failure to comply with regulations and decreased number of research initiatives causes them to be relegated to the second place in this market. With regard to developing economies, Asia-Pacific region is one of the fastest growing markets for NASH therapeutics and is expected to have a double digit growth rate during the analysis period. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people afflicted with these conditions- a number which is expected to increase up to 30 fold by 2030. Furthermore, the exorbitant price of the physical therapeutics currently used to treat fatty liver diseases is raising the demand for pharmaceutical therapies as they are comparatively economical.

KEY BENEFITS

  • Various opportunities for non alcoholic fatty liver disease therapeutics present in developed as well as developing economies are thoroughly assessed
  • Substitute treatments and their potential impact on NASH therapeutics are strategically quantified in the report
  • Opportunities from a business perspective latent in the Asia-Pacific region are brought to light
  • Market dimensions of diagnostic techniques used in NASH monitoring provide a clear outline of the NASH therapeutics research market
  • Geography-wise segmentation of clinical trials is conducted to provide strategic intelligence to the stakeholder
  • Pipeline analysis for the key NASH therapeutics under clinical research provides market intelligence needed for commercialization
  • Detailed analysis of market dynamics provides intelligence about market competencies according to segments
  • In depth analysis of key players operating in the fatty liver disease therapeutics market is conducted according to regions
  • Drivers and factors limiting market expansion are studied in detail
  • Comprehensive and quantitative data about changing market trends, competition and opportunities in NASH market is provided in the report
  • SWOT analysis of companies would help stakeholders make strategic decisions
  • Deep dive analysis of key market players and strategies adopted by them would provide valuable information regarding the top contenders in the market

KEY DELIVERABLES

Global Non-alcoholic Steatohepatitis market is categorized into pipeline therapeutic types and geography.

MARKET BY THERAPEUTICS

  • GFT505
  • Obeticholic Acid (INT-747)
  • Simtuzumab and Liraglutide (Victoza)
  • Vitamin E
  • Pioglitazone
  • Placebo

MARKET BY GEOGRAPHY

  • North America NASH drugs market
    • GFT505
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazone
    • Placebo
  • Europe NASH drugs market
    • GFT505
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazone
    • Placebo
  • Asia-Pacific NASH drugs market
    • GFT505
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazone
    • Placebo
  • LAMEA NASH drugs market
    • GFT505
    • Obeticholic Acid (INT-747)
    • Simtuzumab and Liraglutide (Victoza)
    • Vitamin E
    • Pioglitazone
    • Placebo

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Key Benefits
  • 1.2. Key Market Segment
  • 1.3. Key Audiences
    • 1.3.1. Research Methodology
    • 1.3.2. Primary Research
    • 1.3.3. Secondary Research
    • 1.3.4. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

CHAPTER 3 - MARKET BEYOND: WHAT TO EXPECT BY 2025

  • 3.1. Moderate growth scenario
  • 3.2. Rapid growth scenario
  • 3.3. Diminishing growth scenario

CHAPTER 4 - MARKET OVERVIEW

  • 4.1. Market Definition and Scope
  • 4.2. Key Findings
    • 4.2.1. Top Factors Impacting Global Non-alcoholic Steatohepatitis Market
    • 4.2.2. Top Investment Pockets
  • 4.3. Impeding opportunities for NASH
  • 4.4. Incongruity about preventative role of Fructose
  • 4.5. Dos and Don'ts For Nonalcoholic Fatty Liver Disease Patients
    • 4.5.1. Alcohol Intake
    • 4.5.2. Use of statin
    • 4.5.3. Use of Hepatotoxic Drugs
    • 4.5.4. Vaccination for Hepatitis A and B
  • 4.6. Prevalence of nonalcoholic fatty liver disease in Asia-Pacific Region
    • 4.6.1. Prevalence of NAFLD in China
    • 4.6.2. Prevalence of NAFLD in India
    • 4.6.3. Prevalence of NAFLD in Japan
    • 4.6.4. Prevalence of NAFLD in Australia
  • 4.7. Pipeline Therapeutics
    • 4.7.1. Phase I
    • 4.7.2. Phase II
    • 4.7.3. Phase III
  • 4.8. Diagnostic Techniques
    • 4.8.1. Laboratory Evaluation
    • 4.8.2. Imaging
      • 4.8.2.1. Ultrasonography (US)
      • 4.8.2.2. Computed Tomography (CT)
      • 4.8.2.3. Magnetic Resonance Imaging (MRI) and Proton Magnetic Resonance Spectroscopy (MRS)
      • 4.8.2.4. Transient Elastography
    • 4.8.3. Liver Biopsy
    • 4.8.4. Biomarker diagnostics
      • 4.8.4.1. Common Biomarkers
      • 4.8.4.2. Novel Biomarkers
  • 4.9. Treatment Therapies
    • 4.9.1. Pharmacologic therapy
    • 4.9.2. Steatosis/insulin resistance
    • 4.9.3. Anti-cytokines
    • 4.9.4. Surgical Interventions
  • 4.10. Clinical Trials
  • 4.11. Market Dynamics
    • 4.11.1. Drivers
      • 4.11.1.1. Rampant rate of obesity and diabetes globally
      • 4.11.1.2. Acceleration in initiatives for research and development activities
    • 4.11.2. Restraints
      • 4.11.2.1. Slower development of therapeutics for NASH
      • 4.11.2.2. Blurred understanding of pathophysiology of NASH
      • 4.11.2.3. Inefficient diagnostic technology for NASH
    • 4.11.3. Opportunities
      • 4.11.3.1. Biomarker technologies in diagnosis of NASH
      • 4.11.3.2. Launches of novel therapeutic in 2017

CHAPTER 5 - GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET BY DRUG TYPES

  • 5.1. GFT505
    • 5.1.1. Competitive scenario
    • 5.1.2. Market size and forecast
  • 5.2. Obeticholic Acid (INT-747)
    • 5.2.1. Competitive scenario
    • 5.2.2. Market size and forecast
  • 5.3. Simtuzumab and Liraglutide (Victoza)
    • 5.3.1. Competitive scenario
    • 5.3.2. Market size and forecast
  • 5.4. Vitamin E
    • 5.4.1. Competitive scenario
    • 5.4.2. Market size and forecast
  • 5.5. Poglitazone
    • 5.5.1. Competitive scenario
    • 5.5.2. Market size and forecast
  • 5.6. Placebo
    • 5.6.1. Market size and forecast

CHAPTER 6 - GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET (PIPELINE DRUG ANALYSIS)BY GEOGRAPHY, 2013-20206

  • 6.1. North America
    • 6.1.1. Market size and forecast by pipeline drug types
  • 6.2. Europe
    • 6.2.1. Market size and forecast by pipeline drug types
  • 6.3. Asia-Pacific
    • 6.3.1. Market size and forecast by pipeline drug types
  • 6.4. LAMEA
    • 6.4.1. Market size and forecast by pipeline drug types

CHAPTER 7 - COMPANY PROFILES

  • 7.1. Genfit
    • 7.1.1. Overview
    • 7.1.2. Company snapshot
    • 7.1.3. Financial performance
    • 7.1.4. Strategic moves and developments
    • 7.1.5. SWOT analysis
  • 7.2. Gilead Science
    • 7.2.1. Overview
    • 7.2.2. Company snapshot
    • 7.2.3. Strategic moves and developments
    • 7.2.4. SWOT analysis
  • 7.3. Novo Nordisk
    • 7.3.1. Overview
    • 7.3.2. Company snapshot
    • 7.3.3. Financial performance
    • 7.3.4. Strategic moves and developments
    • 7.3.5. SWOT analysis

7.4. Intercepts Pharmaceuticals

  • 7.4.1. Overview
    • 7.4.2. Company snapshot
    • 7.4.3. Strategic moves and developments
    • 7.4.4. SWOT analysis
  • 7.5. Enzo Biochem, Inc.
    • 7.5.1. Overview
    • 7.5.2. Company snapshot
    • 7.5.3. Financial performance
    • 7.5.4. Strategic moves and developments
    • 7.5.5. SWOT analysis
  • 7.6. Raptor Pharmaceutical Corp.
    • 7.6.1. Overview
    • 7.6.2. Company snapshot
    • 7.6.3. Financial performance
    • 7.6.4. Strategic moves and developments
    • 7.6.5. SWOT analysis

LIST OF TABLES:

  • TABLE 1: Non-alcoholic steatohepatitis moderate growth scenario market revenue by geography, 2020-2025 ($million)
  • TABLE 2: Non-alcoholic steatohepatitis rapid growth scenario market revenue by geography, 2020-2025 ($million)
  • TABLE 3: Non-alcoholic steatohepatitis Diminishing growth scenario market revenue by geography, 2020-2025 ($million)
  • TABLE 4: Liver disease deaths in Australia (2012)
  • TABLE 5: Terminologies related to non alcoholic fatty liver diseases
  • TABLE 6: Therapies available for NASH/NAFLD
  • TABLE 7: Clinical trials initiated from 2012 for NASH therapeutics
  • TABLE 8: Global Nonalcoholic Steatohepatitis therapeutics market, by types, 2013-2020 ($ Million)
  • TABLE 9: Global GFT505 NASH therapeutics revenue by geography, 2013-2020, ($ millions)
  • TABLE 10: Global Obeticholic Acid NASH therapeutics market by geography, 2013-2020 ($ million)
  • TABLE 11: Key regional diabetes healthcare facts (2013)
  • TABLE 12: Global Simtuzumab and Liraglutide (Victoza) NASH therapeutics market by geography, 2013-2020 ($ million)
  • TABLE 13: Global vitamin E NASH therapeutics market by geography, 2013-2020 ($ million)
  • TABLE 14: List of key Pioglitazone brands available in the market
  • TABLE 15: Global Pioglitazone NASH therapeutics market by geography, 2013-2020 ($ million)
  • TABLE 16: Global Placebos NASH therapeutics market by geography, 2013-2020 ($ million)
  • TABLE 17: Global non-alcoholic Steatohepatitis market by geography, 2013-2020 ($million)
  • TABLE 18: North America NASH therapeutics market by therapeutics, 2013-2020 ($ million)
  • TABLE 19: european NASH therapeutics market by therapeutics, 2013-2020 ($ million)
  • TABLE 20: Asia-Pacific NASH therapeutics market by therapeutics, 2013-2020 ($ million)
  • TABLE 21: Prevalence of metabolic syndrome in Americas (2014)
  • TABLE 22: Prevalence of NAFLD in high risk populations in America (2014)
  • TABLE 23: LAMEA NASH therapeutics market by therapeutics, 2013-2020 ($ million)
  • TABLE 24: Expenses incurred in conducting clinical trials (2013)

LIST OF FIGURES:

  • FIG. 1: Top factors impacting global non-alcoholic Steatohepatitis (2014-2020)
  • FIG. 2: Top investment pockets of NASH pipelines therapeutics, 2020, ($ million)
  • FIG. 3: Progression of Non-alcoholic fatty liver disease
  • FIG. 4: Number of incidences of Diabetes Globally, by geography (2000, 2011 & 2030)
  • FIG. 5: SWOT Analysis of Genfit
  • FIG. 6: SWOT Analysis of Gilead Science
  • FIG. 7: Business performance of Novo Nordisk by business units (2013)
  • FIG. 8: Market Share of Insulin unit by volume (Volume Mt)
  • FIG. 9: SWOT Analysis of Novo Nordisk
  • FIG. 10: SWOT Analysis of Intercepts Pharmaceuticals
  • FIG. 11: Business performance of Enzo Biochem, Inc. by segments (2013)
  • FIG. 12: Business performance of Enzo Biochem, Inc. by geography (2013)
  • FIG. 13: SWOT Analysis of Enzo Biochem, Inc.
  • FIG. 14: SWOT Analysis of Raptor Pharmaceutical Corp.
Back to Top